

# Případ 767

Zdeněk K I N K O R



**XXVII. Martinský bioptický seminář**

**2021**







## Pozadí případu



- chlapec **12** let  
bolesti zápěstí, klin. dg. **cystický enchondrom** dist. radia  
- **dvě ložiska** → část RTG dokumentace se ztratila ...?
- Dg. vyšetřujícího patologa - **osteoblastom** vs. **osteosarkom**?
- II. čtení - s rozpaky **epiteloidní hemangioendoteliom ...**
- předneseno na fóru patologů - dg. **nebyla všeobecně přijata ?**
- po **4** letech **revize diagnózy ...**



























# FISH (break apart) analýza zlomu genu *FOSB* (19q13.32)





**kontrola**




**tumor**





**NGS**  
 Archer FusionPlex  
 SAR5 panel  
**RT-PCR / Sanger seq.**



## Definitivní diagnóza

**Pseudomyogenní  
hemangioendoteliom**

## Diferenciální diagnóza

**Epiteloidní sarkom**

**Leiomyosarkom**

**Osteoblastom**

**Neosifikující fibrom**

**Metastáza karcinomu**

---

**Jiné vaskulární léze**



Mirra JM et al.

**The fibroma-like variant of epithelioid sarcoma: a fibrohistiocytic/myoid cell lesion often confused with benign and malignant spindle cell tumors.**

**Cancer 1992; 9: 1382-1395.**

incompletely characterized. We examined 50 cases of this distinctive tumor to evaluate histologic, immunophenotypic, and clinical features. There was a 4.6:1 male predominance (mean age, 31 y; 82%  $\leq$  40 y). Half of the patients presented with

1 patient was alive with unknown disease status, 2 patients were alive with recurrent disease, and 1 patient died of the disease. In summary, we describe a distinctive type of rarely metastasizing ("intermediate") tumor affecting mainly young men and usually

Billings SD et al.

**Epithelioid sarcoma-like hemangioendothelioma.**


**Am J Surg Pathol 2003; 27: 48-57.**

**Abstract:** Pseudomyogenic hemangioendothelioma (PMH) is a well-recognized neoplasm that usually arises in the soft tissue; concurrent bone involvement occurs in 24% of cases. PMH of bone without soft tissue involvement is rare. We describe the clinicopathologic findings of 10 such cases, the largest series reported to date. The study included 9 male and 1 female patient; their ages ranged from 12 to 74 years (mean, 36.7 y). All

static carcinoma. Because of its rarity, unusual presentation, and morphology, accurate diagnosis can be challenging.

**Key Words:** pseudomyogenic hemangioendothelioma, vascular tumor, bone

(*Am J Surg Pathol* 2016;40:587-598)















## Pseudomyogenní hemangioendoteliom (PMH)



Inyang A et al. AJSAP 2016

- indolentní, **ale** recidivuje; **1x** meta
- t(7;19) ***SERPINE1 - FOSB***  
***ACTB - FOSB***
- Dif. Dg.: **EH, EHE, angioSA,**  
epithelioid sarcoma, carcinoma,  
rhabdomyoSA, melanoma, osteoSA,  
PEComa, leiomyosarcoma, IMT,  
osteoblastoma ...
- jde a priori o **vaskulární lézi**



Correspondence


## Novel **EGFL7-FOSB** fusion in pseudomyogenic haemangioendothelioma with widely metastatic disease

Melanie H Hakar, Kevin White, Barry G Hansford, Jeff Swensen, Jessica L Davis ✉


First published: 07 February 2021 | <https://doi.org/10.1111/his.14349>

 Related

 Information




## BIOLOGIE



## MORFOLOGIE


**značný překryv !**



## GENETIKA




# Epiteloidní hemangioendoteliom (EHE)



- bez cévních formací
- <35% metastazuje (**maligní léze**)
- měkké tkáně/kosti, játra, plíce
- IHC - **CAMTA1**, exprese **CK**
  - **WWTR1 - CAMTA1** (95%)
  - **YAP1 - TFE3** (indolentní ?)
- Dif.Dg. - EH, EAS, karcinom mezoteliom...



# Epiteloidní hemangiom (**atypický/buněčný**) (EH)



- **multifokální, biologicky benigní**

ORIGINAL ARTICLE

## Frequent *FOS* Gene Rearrangements in Epithelioid Hemangioma

*A Molecular Study of 58 Cases With Morphologic Reappraisal*

Shih-Chiang Huang, MD,\*† Lei Zhang, MD,† Yun-Shao Sung, MSc,† Chun-Liang Chen, MSc,†  
Thomas Krausz, MD,‡ Brendan C. Dickson, MD,§ Yu-Chien Kao, MD,||  
Narasimhan P. Agaram, MBBS,† Christopher D.M. Fletcher, MD, FRCPath,¶  
and Cristina R. Antonescu, MD†

- **atypie, nekróza, zánětlivá**

GENES, CHROMOSOMES & CANCER 52:951-959 (2014)

## *ZFP36-FOSB* Fusion Defines a Subset of Epithelioid Hemangioma with Atypical Features

Cristina R. Antonescu,<sup>1\*</sup> Hsiao-Wei Chen,<sup>1</sup> Lei Zhang,<sup>1</sup> Yun-Shao Sung,<sup>1</sup> David Panicek,<sup>2</sup> Narasimhan P. Agaram,<sup>3</sup>  
Brendan C. Dickson,<sup>2</sup> Thomas Krausz,<sup>4</sup> and Christopher D. Fletcher<sup>5\*</sup>

<sup>1</sup>Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY

<sup>2</sup>Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY

<sup>3</sup>Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada

<sup>4</sup>Department of Pathology, University of Chicago, Chicago, IL

<sup>5</sup>Department of Pathology, Brigham and Women's Hospital, Boston, MA

~ **50%**  
bone  
soft tissue

- ***WWTR1 - FOSB***



Nedávný případ

za 6 měsíců

Konzultace / II. čtení biopsie:



Epiteloidní Hemangioendoteliom, susp. **Angiosarkom** ?



1241/21









**H-caldesmon**



**aktin**

IHC – FOS / FOSB, CAMTA1 **negativní**

GEN – NGS Illumina ArcherPlex-SAR6 - **negativní**

**Dg.: Atypický epitelooidní hemangiom**






## Novel *GATA6-FOXO1* fusions in a subset of epithelioid hemangioma

Cristina R. Antonescu<sup>1</sup> · Shih-Chiang Huang<sup>2</sup> · Yun-Shao Sung<sup>1</sup> · Lei Zhang<sup>1</sup> · Burkhard M. Helmke<sup>3</sup> · Martina Kirchner<sup>4</sup> · Albrecht Stenzinger<sup>4</sup> · Gunhild Mechtersheimer<sup>4</sup>


sekvenace

**FOS/FOSB** negativních  
EH napodobujících EHE

kožní léze, hlava, krk  
solidní, vasoformativní  
indolentní průběh



# Epiteloidní angiosarkom (EAS)



CK Cam5.2

- **high-grade, nekrózy, prokrvácení solidní - není vazoformativní**
- **Dif. Dg.: EH, EHE, karcinom (CK)...**
- **primární vs sekundární**  
ampl. **MYC, FLT4; PTPRB**  
mut. **PLCG1/KDR**
- **CIC-LEUTX; CIC mut. !**
  - mladí lidé, viscerálně, agresivní
  - solidní epiteloidní (vřetenité)
  - nejsou vazoformativní
  - genová exprese jako CIC-DUX4small cell Ewing-like sarkomy ?

## Epiteloidní vaskulární léze - SHRNU TÍ

- biologicky, morfologicky a geneticky **heterogenní**
- **multifokální** - kůže, měkké tkáně, přilehlá kost
- RTG **nepříliš relevantní** v predikci morfologie
- histologie však někdy nepříjemně **PODOBNÁ**
  - **EH** - vřetenobuněčný, atypie, nekróza, destrukce kortikalis !
- **genetika** je užitečná - FOS/FOSB, CIC, CAMTA1, TFE3
- **Dif.Dg.** - CA, epiteloidní SA, melanom, PECom, mezoteliom



# Genetika mnohdy **klíčová**; **IHC užitečná** pro základní triage

**Table 1** Genetic alterations in vascular neoplasms and useful immunohistochemical markers

Neoplasm	Genetic alteration (prevalence)	Immunohistochemical markers (sensitivity)
Epithelioid hemangioma	<i>WWTR1-FOSB</i> } 20% cellular <i>ZFP36-FOSB</i> } subtype <i>FOS-VIM</i> } <i>FOS-MBLN1</i> } 50% cellular <i>FOS-lincRNA</i> } subtype <i>FOS-(unknown)</i> }	FOSB FOS [ 75% conventional subtype 100% ALHE subtype 10% cellular subtype
Tufted angioma/kaposiform hemangioendothelioma	<i>GNA14</i> mutation (unknown)	No specific markers
Anastomosing hemangioma Hepatic small vessel neoplasm Lobular capillary hemangioma	<i>GNA11</i> mutation } <i>GNA14</i> mutation } ? nearly <i>GNAQ</i> mutation } 100%	No specific markers
Composite hemangioendothelioma	<i>PTBP1-MAML2</i> (rare) <i>EPC1-PHC2</i> (rare)	Synaptophysin (subset of aggressive cases; unknown sensitivity overall)
Pseudomyogenic hemangioendothelioma	<i>SERPINE1-FOSB</i> (? 55%) <i>ACTB-FOSB</i> (? 45%)	FOSB (nearly 100%)
Epithelioid hemangioendothelioma	<i>WWTR1-CAMTA1</i> (85%) <i>YAP1-TFE3</i> (5%)	CAMTA1 (85%) TFE3 (5%)
Post-radiation angiosarcoma	<i>MYC</i> amplification (100%) <i>FLT4</i> amplification (25%) <i>PTPBR</i> mutation (45%) <i>PLCG1</i> mutation (15%)	MYC (nearly 100%)
Primary angiosarcoma	Complex karyotype (? 25%) <i>KDR</i> mutation (25%) <i>CIC</i> rearrangement or point mutation (10%)	No specific markers


ALHE angiolymphoid hyperplasia with eosinophilia



## A unique epithelioid vascular neoplasm of bone characterized by *EWSR1/FUS-NFATC1/2* fusions

Nooshin K. Dashti<sup>1</sup> | Brendan C. Dickson<sup>2</sup> | Lei Zhang<sup>3</sup> | Ziyu Xie<sup>3</sup> | Gunnlaugur Pétur Nielsen<sup>4</sup> | Cristina R. Antonescu<sup>3</sup>

**sekvenace fúzně negativních  
(CAMTA1, WWTR1, TFE3,  
YAP1, FOS, FOSB)  
epiteloidních cévních lézí**



**bez amplifikace !**

skelet

destruktivní,  
agresivně rostoucí

vazoformativní, solidní  
atypie, rhabdoidní

napodobuje

EH, EHE, PMH, CHE, AS

recidivy, **nemetastázuje**





Děkuji za pozornost

